Literature DB >> 34406889

Drug metabolic stability in early drug discovery to develop potential lead compounds.

Siva Nageswara Rao Gajula1, Nimisha Nadimpalli1, Rajesh Sonti1.   

Abstract

Knowledge of the metabolic stability of a new drug substance eliminated by biotransformation is essential for envisaging the pharmacokinetic parameters required for deciding drug dosing and frequency. Strategies aimed at modifying lead compounds may improve metabolic stability, thereby reducing the drug dosing frequency. Replacement of selective hydrogens with deuterium can effectively enhance the drug's metabolic stability by increasing the biological half-life. Further, cyclization, change in ring size, and chirality can substantially improve the metabolic stability of drugs. The microsomal t1/2 approach for measuring drug in vitro intrinsic clearance by automated LC-MS/MS offers sensitive high-throughput screens with reliable data. The obtained in vitro intrinsic clearance from metabolic stability data helps predict the drug's in vivo total clearance using different scaling factors and hepatic clearance models. This review summarizes all the recent approaches and technological advancements in metabolic stability studies for narrowing down the potential lead compounds in drug discovery. Further, we summarized the potential pitfalls and assumptions made during the in vivo intrinsic clearance estimation from in vitro intrinsic clearance.

Entities:  

Keywords:  ADI-OPI-MS; Drug discovery; deuterium incorporation; high-throughput screening; intrinsic clearance; metabolic stability; sample pooling

Mesh:

Substances:

Year:  2021        PMID: 34406889     DOI: 10.1080/03602532.2021.1970178

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  1 in total

Review 1.  Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer.

Authors:  Tafere Mulaw Belete
Journal:  Drug Des Devel Ther       Date:  2022-10-04       Impact factor: 4.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.